tirzepatide weight loss expected Adults with obesity using maintain 'remarkable' at 88 weeks Tirzepatide weight loss timeline: what

The Mounjaro manufacturer is likely trying to distance itself from Ozempic, which has been largely used and abused off-label

Authors' contributions AS, JCH, MEL, DAK, DSP, and WT conceived and designed the experiments

The drug is indicated for chronic weight management in patients with a body mass index (BMI) of 27 kg/m2 or greater who have a least one weight-related ailment or in patients with a BMI of 30 kg/m2 or greater

The ideal choices share several characteristics: they promote muscle preservation during caloric deficit, they enhance rather than impair fat oxidation, they produce minimal water retention, and they have manageable side effect profiles when used responsibly